



**Universiteit
Leiden**
The Netherlands

Designing T-cells with desired T-cell receptor make-up for immunotherapy

Loenen, M.M. van

Citation

Loenen, M. M. van. (2011, April 20). *Designing T-cells with desired T-cell receptor make-up for immunotherapy*. Retrieved from <https://hdl.handle.net/1887/17581>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/17581>

Note: To cite this publication please use the final published version (if applicable).

References

CHAPTER 1 - INTRODUCTION

- Thomas, E. D.**
Bone marrow transplantation from bench to bedside. *Ann. N. Y. Acad. Sci.* 1995; vol 770: pp 34-41.
- Hale, G., Cobbold, S., and Waldmann, H.**
T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation. *Transplantation* 1988; vol 45: pp 753-759.
- Martin, P. J., Hansen, J. A., Buckner, C. D. et al.**
Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. *Blood* 1985; vol 66: pp 664-672.
- Mitsuyasu, R. T., Champlin, R. E., Gale, R. P. et al.**
Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial. *Ann. Intern. Med.* 1986; vol 105: pp 20-26.
- Apperley, J. F., Jones, L., Hale, G. et al.**
Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. *Bone Marrow Transplant.* 1986; vol 1: pp 53-66.
- Marmont, A. M., Horowitz, M. M., Gale, R. P. et al.**
T-cell depletion of HLA-identical transplants in leukemia. *Blood* 1991; vol 78: pp 2120-2130.
- Weiden, P. L., Flournoy, N., Thomas, E. D. et al.**
Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. *N. Engl. J. Med.* 1979; vol 300: pp 1068-1073.
- Weiden, P. L., Sullivan, K. M., Flournoy, N. et al.**
Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. *N. Engl. J. Med.* 1981; vol 304: pp 1529-1533.
- Collins, R. H., Jr., Rogers, Z. R., Bennett, M. et al.**
Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. *Bone Marrow Transplant.* 1992; vol 10: pp 391-395.
- Higano, C. S., Brixey, M., Bryant, E. M. et al.**
Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect. *Transplantation* 1990; vol 50: pp 175-177.
- Ringden, O., Labopin, M., Gorin, N. C. et al.**
Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia? *Br. J. Haematol.* 2000; vol 111: pp 1130-1137.
- Zittoun, R. A., Mandelli, F., Willemze, R. et al.**
Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. *N. Engl. J. Med.* 1995; vol 332: pp 217-223.
- Gale, R. P., Horowitz, M. M., Ash, R. C. et al.**
Identical-twin bone marrow transplants for leukemia. *Ann. Intern. Med.* 1994; vol 120: pp 646-652.
- Horowitz, M. M., Gale, R. P., Sondel, P. M. et al.**
Graft-versus-leukemia reactions after bone marrow transplantation. *Blood* 1990; vol 75: pp 555-562.
- Kolb, H. J., Schattenberg, A., Goldman, J. M. et al.**
Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. *Blood* 1995; vol 86: pp 2041-2050.
- Slavin, S., Naparstek, E., Nagler, A. et al.**
Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. *Blood* 1996; vol 87: pp 2195-2204.
- Banna, G. L., Aversa, S., Sileri, V. C. et al.**
Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens. *Crit. Rev. Oncol. Hematol.* 2004; vol 51: pp 171-189.
- Giralt, S.**
Reduced-intensity conditioning regimens for hematologic malignancies: what have we learned over the last 10 years? *Hematology. Am. Soc. Hematol. Educ. Program.* 2005; vol 384-389.
- Slavin, S., Nagler, A., Naparstek, E. et al.**
Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. *Blood* 1998; vol 91: pp 756-763.
- von dem Borne, P. A., Starrenburg, C. W., Barge, R. M. et al.**
Comparable engraftment and chimerism kinetics using oral and intravenous fludarabine as part of a reduced intensity conditioning regimen. *Bone Marrow Transplant.* 2008; vol 42: pp 137-138.

21. **von dem Borne, P. A., Starrenburg, C. W., Halkes, S. J. et al.**
Reduced-intensity conditioning allogeneic stem cell transplantation with donor T-cell depletion using alemtuzumab added to the graft ("Camp in the bag"). *Curr. Opin. Oncol.* 2009; vol 21 Suppl 1: pp S27-S29.
22. **Socie, G., Stone, J. V., Wingard, J. R. et al.**
Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. *N. Engl. J. Med.* 1999; vol 341: pp 14-21.
23. **Collins, R. H., Jr., Shpilberg, O., Drobyski, W. R. et al.**
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. *J. Clin. Oncol.* 1997; vol 15: pp 433-444.
24. **Kolb, H. J., Mittermuller, J., Clemm, C. et al.**
Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. *Blood* 1990; vol 76: pp 2462-2465.
25. **Porter, D. L., Collins, R. H., Jr., Hardy, C. et al.**
Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. *Blood* 2000; vol 95: pp 1214-1221.
26. **Dazzi, F., Szydlo, R. M., Craddock, C. et al.**
Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. *Blood* 2000; vol 95: pp 67-71.
27. **Mackinnon, S., Papadopoulos, E. B., Carabasi, M. H. et al.**
Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. *Blood* 1995; vol 86: pp 1261-1268.
28. **Porter, D. L., Collins, R. H., Jr., Shpilberg, O. et al.**
Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions. *Biol. Blood Marrow Transplant.* 1999; vol 5: pp 253-261.
29. **Kroger, N., Kruger, W., Renges, H. et al.**
Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma. *Br. J. Haematol.* 2001; vol 112: pp 421-423.
30. **Levine, J. E., Braun, T., Penza, S. L. et al.**
Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. *J. Clin. Oncol.* 2002; vol 20: pp 405-412.
31. **Lokhorst, H. M., Schattenberg, A., Cornelissen, J. J. et al.**
Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. *J. Clin. Oncol.* 2000; vol 18: pp 3031-3037.
32. **Salama, M., Nevill, T., Marcellus, D. et al.**
Donor leukocyte infusions for multiple myeloma. *Bone Marrow Transplant.* 2000; vol 26: pp 1179-1184.
33. **Frey, N. V. and Porter, D. L.**
Graft-versus-host disease after donor leukocyte infusions: presentation and management. *Best. Pract. Res. Clin. Haematol.* 2008; vol 21: pp 205-222.
34. **Falkenburg, J. H. and Willemze, R.**
Minor histocompatibility antigens as targets of cellular immunotherapy in leukaemia. *Best. Pract. Res. Clin. Haematol.* 2004; vol 17: pp 415-425.
35. **Cobbold, M., Khan, N., Pourghesari, B. et al.**
Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. *J. Exp. Med.* 2005; vol 202: pp 379-386.
36. **Einsele, H., Roosnek, E., Rufer, N. et al.**
Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. *Blood* 2002; vol 99: pp 3916-3922.
37. **Peggs, K. S., Verfuert, S., Pizzey, A. et al.**
Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. *Lancet* 2003; vol 362: pp 1375-1377.
38. **Riddell, S. R., Watanabe, K. S., Goodrich, J. M. et al.**
Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. *Science* 1992; vol 257: pp 238-241.
39. **Walter, E. A., Greenberg, P. D., Gilbert, M. J. et al.**
Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. *N. Engl. J. Med.* 1995; vol 333: pp 1038-1044.
40. **Bollard, C. M., Aguilar, L., Straathof, K. C. et al.**
Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. *J. Exp. Med.* 2004; vol 200: pp 1623-1633.
41. **Khanna, R., Bell, S., Sherritt, M. et al.**
Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. *Proc. Natl. Acad. Sci. U. S. A.* 1999; vol 96: pp 10391-10396.
42. **Rooney, C. M., Smith, C. A., Ng, C. Y. et al.**
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. *Lancet* 1995; vol 345: pp 9-13.
43. **Savoldo, B., Goss, J. A., Hammer, M. M. et al.**
Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). *Blood* 2006; vol 108: pp 2942-2949.
44. **Heslop, H. E., Slobod, K. S., Pule, M. A. et al.**
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. *Blood* 2010; vol 115: pp 925-935.
45. **Warren, E. H., Fujii, N., Akatsuka, Y. et al.**
Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. *Blood* 2010; vol 115: pp 3869-3878.
46. **Falkenburg, J. H., Wafelman, A. R., Joosten, P. et al.**
Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. *Blood* 1999; vol 94: pp 1201-1208.

47. **Marijt, E., Wafelman, A., van der Hoorn, M. et al.**
Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stem cell transplantation. *Haematologica* 2007; vol 92: pp 72-80.
48. **Gattinoni, L., Klebanoff, C. A., Palmer, D. C. et al.**
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. *J. Clin. Invest* 2005; vol 115: pp 1616-1626.
49. **Nijmeijer, B. A., Willemze, R., and Falkenburg, J. H.**
An animal model for human cellular immunotherapy: specific eradication of human acute lymphoblastic leukemia by cytotoxic T lymphocytes in NOD/scid mice. *Blood* 2002; vol 100: pp 654-660.
50. **Sauer, M. G., Ericson, M. E., Weigel, B. J. et al.**
A novel system for simultaneous in vivo tracking and biological assessment of leukemia cells and ex vivo generated leukemia-reactive cytotoxic T cells. *Cancer Res.* 2004; vol 64: pp 3914-3921.
51. **Klein, L., Hinterberger, M., Wirmsberger, G. et al.**
Antigen presentation in the thymus for positive selection and central tolerance induction. *Nat. Rev. Immunol.* 2009; vol 9: pp 833-844.
52. **Singer, A., Adoro, S., and Park, J. H.**
Lineage fate and intense debate: myths, models and mechanisms of CD4- versus CD8-lineage choice. *Nat. Rev. Immunol.* 2008; vol 8: pp 788-801.
53. **Jorgensen, J. L., Reay, P. A., Ehrlich, E. W. et al.**
Molecular components of T-cell recognition. *Annu. Rev. Immunol.* 1992; vol 10: pp 835-873.
54. **Arden, B.**
Conserved motifs in T-cell receptor CDR1 and CDR2: implications for ligand and CD8 co-receptor binding. *Curr. Opin. Immunol.* 1998; vol 10: pp 74-81.
55. **Vyas, J. M., van, d., V, and Ploegh, H. L.**
The known unknowns of antigen processing and presentation. *Nat. Rev. Immunol.* 2008; vol 8: pp 607-618.
56. **Doyle, C. and Strominger, J. L.**
Interaction between CD4 and class II MHC molecules mediates cell adhesion. *Nature* 1987; vol 330: pp 256-259.
57. **Konig, R., Shen, X., and Germain, R. N.**
Involvement of both major histocompatibility complex class II alpha and beta chains in CD4 function indicates a role for ordered oligomerization in T cell activation. *J. Exp. Med.* 1995; vol 182: pp 779-787.
58. **Wang, J. H., Meijers, R., Xiong, Y. et al.**
Crystal structure of the human CD4 N-terminal two-domain fragment complexed to a class II MHC molecule. *Proc. Natl. Acad. Sci. U. S. A* 2001; vol 98: pp 10799-10804.
59. **Arcaro, A., Gregoire, C., Bakker, T. R. et al.**
CD8beta endows CD8 with efficient coreceptor function by coupling T cell receptor/CD3 to raft-associated CD8/p56(lck) complexes. *J. Exp. Med.* 2001; vol 194: pp 1485-1495.
60. **Salter, R. D., Benjamin, R. J., Wesley, P. K. et al.**
A binding site for the T-cell co-receptor CD8 on the alpha 3 domain of HLA-A2. *Nature* 1990; vol 345: pp 41-46.
61. **Baume, D. M., Caligiuri, M. A., Manley, T. J. et al.**
Differential expression of CD8 alpha and CD8 beta associated with MHC-restricted and non-MHC-restricted cytolytic effector cells. *Cell Immunol.* 1990; vol 131: pp 352-365.
62. **Goodman, T. and Lefrancois, L.**
Expression of the gamma-delta T-cell receptor on intestinal CD8+ intraepithelial lymphocytes. *Nature* 1988; vol 333: pp 855-858.
63. **Guy-Grand, D., Cerf-Bensussan, N., Malissen, B. et al.**
Two gut intraepithelial CD8+ lymphocyte populations with different T cell receptors: a role for the gut epithelium in T cell differentiation. *J. Exp. Med.* 1991; vol 173: pp 471-481.
64. **Janeway, C. A., Jr.**
The T cell receptor as a multicomponent signalling machine: CD4/CD8 coreceptors and CD45 in T cell activation. *Annu. Rev. Immunol.* 1992; vol 10: pp 645-674.
65. **Rocha, B., Vassalli, P., and Guy-Grand, D.**
The V beta repertoire of mouse gut homodimeric alpha CD8+ intraepithelial T cell receptor alpha/beta + lymphocytes reveals a major extrathymic pathway of T cell differentiation. *J. Exp. Med.* 1991; vol 173: pp 483-486.
66. **Zamoyska, R.**
The CD8 coreceptor revisited: one chain good, two chains better. *Immunity.* 1994; vol 1: pp 243-246.
67. **Blanc, D., Bron, C., Gabert, J. et al.**
Gene transfer of the Ly-3 chain gene of the mouse CD8 molecular complex: co-transfer with the Ly-2 polypeptide gene results in detectable cell surface expression of the Ly-3 antigenic determinants. *Eur. J. Immunol.* 1988; vol 18: pp 613-619.
68. **Gorman, S. D., Sun, Y. H., Zamoyska, R. et al.**
Molecular linkage of the Ly-3 and Ly-2 genes. Requirement of Ly-2 for Ly-3 surface expression. *J. Immunol.* 1988; vol 140: pp 3646-3653.
69. **Norment, A. M. and Littman, D. R.**
A second subunit of CD8 is expressed in human T cells. *EMBO J.* 1988; vol 7: pp 3433-3439.
70. **Bosselut, R., Kubo, S., Guinter, T. et al.**
Role of CD8beta domains in CD8 coreceptor function: importance for MHC I binding, signaling, and positive selection of CD8+ T cells in the thymus. *Immunity.* 2000; vol 12: pp 409-418.
71. **Renard, V., Romero, P., Vivier, E. et al.**
CD8 beta increases CD8 coreceptor function and participation in TCR-ligand binding. *J. Exp. Med.* 1996; vol 184: pp 2439-2444.
72. **Witte, T., Spoerl, R., and Chang, H. C.**
The CD8beta ectodomain contributes to the augmented coreceptor function of CD8alpha beta heterodimers relative to CD8alpha alpha homodimers. *Cell Immunol.* 1999; vol 191: pp 90-96.
73. **Barber, E. K., Dasgupta, J. D., Schlossman, S. F. et al.**
The CD4 and CD8 antigens are coupled to a protein-tyrosine kinase (p56lck) that phosphorylates the CD3 complex. *Proc. Natl. Acad. Sci. U. S. A* 1989; vol 86: pp 3277-3281.

74. **Shaw, A. S., Amrein, K. E., Hammond, C. et al.**
The lck tyrosine protein kinase interacts with the cytoplasmic tail of the CD4 glycoprotein through its unique amino-terminal domain. *Cell* 1989; vol 59: pp 627-636.
75. **Turner, J. M., Brodsky, M. H., Irving, B. A. et al.**
Interaction of the unique N-terminal region of tyrosine kinase p56lck with cytoplasmic domains of CD4 and CD8 is mediated by cysteine motifs. *Cell* 1990; vol 60: pp 755-765.
76. **Veillette, A., Bookman, M. A., Horak, E. M. et al.**
The CD4 and CD8 T cell surface antigens are associated with the internal membrane tyrosine-protein kinase p56lck. *Cell* 1988; vol 55: pp 301-308.
77. **Veillette, A., Zuniga-Pflucker, J. C., Bolen, J. B. et al.**
Engagement of CD4 and CD8 expressed on immature thymocytes induces activation of intracellular tyrosine phosphorylation pathways. *J. Exp. Med.* 1989; vol 170: pp 1671-1680.
78. **Balamuth, F., Brogdon, J. L., and Bottomly, K.**
CD4 raft association and signaling regulate molecular clustering at the immunological synapse site. *J. Immunol.* 2004; vol 172: pp 5887-5892.
79. **Fragoso, R., Ren, D., Zhang, X. et al.**
Lipid raft distribution of CD4 depends on its palmitoylation and association with Lck, and evidence for CD4-induced lipid raft aggregation as an additional mechanism to enhance CD3 signaling. *J. Immunol.* 2003; vol 170: pp 913-921.
80. **Pang, D. J., Hayday, A. C., and Bijlmakers, M. J.**
CD8 Raft localization is induced by its assembly into CD8alpha beta heterodimers, Not CD8alpha alpha homodimers. *J. Biol. Chem.* 2007; vol 282: pp 13884-13894.
81. **Janssen, E. M., Lemmens, E. E., Wolfe, T. et al.**
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. *Nature* 2003; vol 421: pp 852-856.
82. **Shedlock, D. J. and Shen, H.**
Requirement for CD4 T cell help in generating functional CD8 T cell memory. *Science* 2003; vol 300: pp 337-339.
83. **Janeway, C. A., Jr., Carding, S., Jones, B. et al.**
CD4+ T cells: specificity and function. *Immunol. Rev.* 1988; vol 101: pp 39-80.
84. **Harty, J. T., Tivnereim, A. R., and White, D. W.**
CD8+ T cell effector mechanisms in resistance to infection. *Annu. Rev. Immunol.* 2000; vol 18: pp 275-308.
85. **Paillard, F., Sterkers, G., and Vaquero, C.**
Transcriptional and post-transcriptional regulation of Tcr, CD4 and CD8 gene expression during activation of normal human T lymphocytes. *EMBO J.* 1990; vol 9: pp 1867-1872.
86. **Paillard, F., Sterkers, G., and Vaquero, C.**
Correlation between up-regulation of lymphokine mRNA and down-regulation of Tcr, CD4, CD8 and lck mRNA as shown by the effect of CsA on activated T lymphocytes. *Biochem. Biophys. Res. Commun.* 1992; vol 186: pp 603-611.
87. **Faber, L. M., van Luxemburg-Heijs, S. A., Veenhof, W. F. et al.**
Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity. *Blood* 1995; vol 86: pp 2821-2828.
88. **Heemskerck, M. H., de Paus, R. A., Lurvink, E. G. et al.**
Dual HLA class I and class II restricted recognition of alloreactive T lymphocytes mediated by a single T cell receptor complex. *Proc. Natl. Acad. Sci. U. S. A.* 2001; vol 98: pp 6806-6811.
89. **Lefrancois, L.**
Development, trafficking, and function of memory T-cell subsets. *Immunol. Rev.* 2006; vol 211: pp 93-103.
90. **Sallusto, F., Geginat, J., and Lanzavecchia, A.**
Central memory and effector memory T cell subsets: function, generation, and maintenance. *Annu. Rev. Immunol.* 2004; vol 22: pp 745-763.
91. **Stemberger, C., Neuenhahn, M., Gebhardt, F. E. et al.**
Stem cell-like plasticity of naive and distinct memory CD8+ T cell subsets. *Semin. Immunol.* 2009; vol 21: pp 62-68.
92. **Appay, V., Dunbar, P. R., Callan, M. et al.**
Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. *Nat. Med.* 2002; vol 8: pp 379-385.
93. **Appay, V., van Lier, R. A., Sallusto, F. et al.**
Phenotype and function of human T lymphocyte subsets: Consensus and issues. *Cytometry A* 2008; vol
94. **Hislop, A. D., Gudgeon, N. H., Callan, M. F. et al.**
EBV-specific CD8+ T cell memory: relationships between epitope specificity, cell phenotype, and immediate effector function. *J. Immunol.* 2001; vol 167: pp 2019-2029.
95. **van Leeuwen, E. M., de Bree, G. J., Ten, B., I et al.**
Human virus-specific CD8+ T cells: diversity specialists. *Immunol. Rev.* 2006; vol 211: pp 225-235.
96. **Akatsuka, Y., Nishida, T., Kondo, E. et al.**
Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens. *J. Exp. Med.* 2003; vol 197: pp 1489-1500.
97. **den Haan, J. M., Meadows, L. M., Wang, W. et al.**
The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. *Science* 1998; vol 279: pp 1054-1057.
98. **Vogt, M. H., Goulmy, E., Kloosterboer, F. M. et al.**
UTY gene codes for an HLA-B60-restricted human male-specific minor histocompatibility antigen involved in stem cell graft rejection: characterization of the critical polymorphic amino acid residues for T-cell recognition. *Blood* 2000; vol 96: pp 3126-3132.
99. **Vogt, M. H., de Paus, R. A., Voogt, P. J. et al.**
DFFRY codes for a new human male-specific minor transplantation antigen involved in bone marrow graft rejection. *Blood* 2000; vol 95: pp 1100-1105.
100. **Wang, W., Meadows, L. R., den Haan, J. M. et al.**
Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. *Science* 1995; vol 269: pp 1588-1590.
101. **Brickner, A. G., Warren, E. H., Caldwell, J. A. et al.**
The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing. *J. Exp. Med.* 2001; vol 193: pp 195-206.

102. **den Haan, J. M., Sherman, N. E., Blokland, E. et al.**
Identification of a graft versus host disease-associated human minor histocompatibility antigen.
Science 1995; vol 268: pp 1476-1480.
103. **Pierce, R. A., Field, E. D., Mutis, T. et al.**
The HA-2 minor histocompatibility antigen is derived from a diallelic gene encoding a novel human class I myosin protein.
J. Immunol. 2001; vol 167: pp 3223-3230.
104. **Spierings, E., Brickner, A. G., Caldwell, J. A. et al.**
The minor histocompatibility antigen HA-3 arises from differential protease-mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein.
Blood 2003; vol 102: pp 621-629.
105. **Murata, M., Warren, E. H., and Riddell, S. R.**
A human minor histocompatibility antigen resulting from differential expression due to a gene deletion.
J. Exp. Med. 2003; vol 197: pp 1279-1289.
106. **Griffioen, M., van der Meijden, E. D., Slager, E. H. et al.**
Identification of phosphatidylinositol 4-kinase II beta as HLA class II-restricted target in graft versus leukemia reactivity.
Proc. Natl. Acad. Sci. U. S. A 2008; vol 105: pp 3837-3842.
107. **Spaapen, R. M., Lokhorst, H. M., van den Oudenalder, K. et al.**
Toward targeting B cell cancers with CD4+ CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis.
J. Exp. Med. 2008; vol 205: pp 2863-2872.
108. **Stumpf, A. N., van der Meijden, E. D., van Bergen, C. A. et al.**
Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity.
Blood 2009; vol 114: pp 3684-3692.
109. **Vogt, M. H., van den Muijsenberg, J. W., Goulmy, E. et al.**
The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease.
Blood 2002; vol 99: pp 3027-3032.
110. **de Bueger, M., Bakker, A., van Rood, J. J. et al.**
Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens.
J. Immunol. 1992; vol 149: pp 1788-1794.
111. **Klein, C. A., Wilke, M., Pool, J. et al.**
The hematopoietic system-specific minor histocompatibility antigen HA-1 shows aberrant expression in epithelial cancer cells.
J. Exp. Med. 2002; vol 196: pp 359-368.
112. **Pietz, B. C., Warden, M. B., Duchateau, B. K. et al.**
Multiplex genotyping of human minor histocompatibility antigens.
Hum. Immunol. 2005; vol 66: pp 1174-1182.
113. **Spierings, E., Hendriks, M., Absi, L. et al.**
Phenotype frequencies of autosomal minor histocompatibility antigens display significant differences among populations.
PLoS. Genet. 2007; vol 3: pp e103
114. **van Els, C. A., D'Amato, J., Pool, J. et al.**
Immunogenetics of human minor histocompatibility antigens: their polymorphism and immunodominance.
Immunogenetics 1992; vol 35: pp 161-165.
115. **Fujii, N., Hiraki, A., Ikeda, K. et al.**
Expression of minor histocompatibility antigen, HA-1, in solid tumor cells.
Transplantation 2002; vol 73: pp 1137-1141.
116. **Spierings, E., Gras, S., Reiser, J. B. et al.**
Steric hindrance and fast dissociation explain the lack of immunogenicity of the minor histocompatibility HA-1Arg Null allele.
J. Immunol. 2009; vol 182: pp 4809-4816.
117. **Kircher, B., Stevanovic, S., Urbanek, M. et al.**
Induction of HA-1-specific cytotoxic T-cell clones parallels the therapeutic effect of donor lymphocyte infusion.
Br. J. Haematol. 2002; vol 117: pp 935-939.
118. **Kloosterboer, F. M., van Luxemburg-Heijs, S. A., van Soest, R. A. et al.**
Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells.
Leukemia 2004; vol 18: pp 798-808.
119. **Rufer, N., Wolpert, E., Helg, C. et al.**
HA-1 and the SMCY-derived peptide FIDSYICQV (H-Y) are immunodominant minor histocompatibility antigens after bone marrow transplantation.
Transplantation 1998; vol 66: pp 910-916.
120. **Marijt, W. A., Heemskerck, M. H., Kloosterboer, F. M. et al.**
Hematopoiesis-restricted minor histocompatibility antigens HA-1 or HA-2-specific T cells can induce complete remissions of relapsed leukemia.
Proc. Natl. Acad. Sci. U. S. A 2003; vol 100: pp 2742-2747.
121. **Hambach, L., Vermeij, M., Buser, A. et al.**
Targeting a single mismatched minor histocompatibility antigen with tumor-restricted expression eradicates human solid tumors.
Blood 2008; vol 112: pp 1844-1852.
122. **Dudley, M. E., Yang, J. C., Sherry, R. et al.**
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.
J. Clin. Oncol. 2008; vol 26: pp 5233-5239.
123. **Dembic, Z., Haas, W., Weiss, S. et al.**
Transfer of specificity by murine alpha and beta T-cell receptor genes.
Nature 1986; vol 320: pp 232-238.
124. **Clay, T. M., Custer, M. C., Sachs, J. et al.**
Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity.
J. Immunol. 1999; vol 163: pp 507-513.
125. **Cooper, L. J., Kalos, M., Lewinsohn, D. A. et al.**
Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes.
J. Virol. 2000; vol 74: pp 8207-8212.
126. **Heemskerck, M. H., Hoogeboom, M., de Paus, R. A. et al.**
Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region.
Blood 2003; vol 102: pp 3530-3540.
127. **Heemskerck, M. H., Hoogeboom, M., Hagedoorn, R. et al.**
Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer.
J. Exp. Med. 2004; vol 199: pp 885-894.
128. **Stanislowski, T., Voss, R. H., Lotz, C. et al.**
Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer.
Nat. Immunol. 2001; vol 2: pp 962-970.
129. **Kessels, H. W., Wolkers, M. C., van, d. B. et al.**
Immunotherapy through TCR gene transfer.
Nat. Immunol. 2001; vol 2: pp 957-961.

130. **Morgan, R. A., Dudley, M. E., Wunderlich, J. R. et al.**
Cancer regression in patients after transfer of genetically engineered lymphocytes.
Science 2006; vol 314: pp 126-129.
131. **Xue, S. A., Gao, L., Hart, D. et al.**
Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells.
Blood 2005; vol 106: pp 3062-3067.
132. **Johnson, L. A., Morgan, R. A., Dudley, M. E. et al.**
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.
Blood 2009; vol 114: pp 535-546.
133. **Dudley, M. E., Wunderlich, J. R., Robbins, P. F. et al.**
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.
Science 2002; vol 298: pp 850-854.
134. **Dudley, M. E., Wunderlich, J. R., Yang, J. C. et al.**
Adoptive cell transfer therapy following non-myceloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
J. Clin. Oncol. 2005; vol 23: pp 2346-2357.
135. **Unutmaz, D., KewalRamani, V. N., Marmon, S. et al.**
Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes.
J. Exp. Med. 1999; vol 189: pp 1735-1746.
136. **Cavazzana-Calvo, M., Hacein-Bey, S., de Saint, B. G. et al.**
Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.
Science 2000; vol 288: pp 669-672.
137. **Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P. et al.**
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.
J. Clin. Invest. 2008; vol 118: pp 3132-3142.
138. **Fischer, A., Hacein-Bey-Abina, S., and Cavazzana-Calvo, M.**
20 years of gene therapy for SCID.
Nat. Immunol. 2010; vol 11: pp 457-460.
139. **Aiuti, A., Cattaneo, F., Galimberti, S. et al.**
Gene therapy for immunodeficiency due to adenosine deaminase deficiency.
N. Engl. J. Med. 2009; vol 360: pp 447-458.
140. **Cassani, B., Montini, E., Maruggi, G. et al.**
Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy.
Blood 2009; vol 114: pp 3546-3556.
141. **Blaese, R. M., Culver, K. W., Miller, A. D. et al.**
T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years.
Science 1995; vol 270: pp 475-480.
142. **Ciceri, F., Bonini, C., Marktel, S. et al.**
Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation.
Blood 2007; vol 109: pp 4698-4707.
143. **Recchia, A., Bonini, C., Magnani, Z. et al.**
Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells.
Proc. Natl. Acad. Sci. U. S. A. 2006; vol 103: pp 1457-1462.
144. **Bonini, C., Grez, M., Traversari, C. et al.**
Safety of retroviral gene marking with a truncated NGF receptor.
Nat. Med. 2003; vol 9: pp 367-369.
145. **Newrzela, S., Cornils, K., Li, Z. et al.**
Resistance of mature T cells to oncogene transformation.
Blood 2008; vol 112: pp 2278-2286.
146. **Chervin, A. S., Aggen, D. H., Raseman, J. M. et al.**
Engineering higher affinity T cell receptors using a T cell display system.
J. Immunol. Methods 2008; vol 339: pp 175-184.
147. **Holler, P. D., Holman, P. O., Shusta, E. V. et al.**
In vitro evolution of a T cell receptor with high affinity for peptide/MHC.
Proc. Natl. Acad. Sci. U. S. A. 2000; vol 97: pp 5387-5392.
148. **Kessels, H. W., van, d. B., Spits, H. et al.**
Changing T cell specificity by retroviral T cell receptor display.
Proc. Natl. Acad. Sci. U. S. A. 2000; vol 97: pp 14578-14583.
149. **Robbins, P. F., Li, Y. F., El-Gamil, M. et al.**
Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions.
J. Immunol. 2008; vol 180: pp 6116-6131.
150. **Varela-Rohena, A., Molloy, P. E., Dunn, S. M. et al.**
Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor.
Nat. Med. 2008; vol 14: pp 1390-1395.
151. **Zhao, Y., Bennett, A. D., Zheng, Z. et al.**
High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines.
J. Immunol. 2007; vol 179: pp 5845-5854.
152. **Sadelain, M., Brentjens, R., and Riviere, I.**
The promise and potential pitfalls of chimeric antigen receptors.
Curr. Opin. Immunol. 2009; vol 21: pp 215-223.
153. **Carpenito, C., Milone, M. C., Hassan, R. et al.**
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.
Proc. Natl. Acad. Sci. U. S. A. 2009; vol 106: pp 3360-3365.
154. **Kowolik, C. M., Topp, M. S., Gonzalez, S. et al.**
CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
Cancer Res. 2006; vol 66: pp 10995-11004.
155. **Milone, M. C., Fish, J. D., Carpenito, C. et al.**
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.
Mol. Ther. 2009; vol 17: pp 1453-1464.
156. **Wang, J., Jensen, M., Lin, Y. et al.**
Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains.
Hum. Gene Ther. 2007; vol 18: pp 712-725.
157. **Zhao, Y., Wang, Q. J., Yang, S. et al.**
A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity.
J. Immunol. 2009; vol 183: pp 5563-5574.
158. **Zhong, X. S., Matsushita, M., Plotkin, J. et al.**
Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication.
Mol. Ther. 2010; vol 18: pp 413-420.

159. **Lamers, C. H., Sleijfer, S., Vulto, A. G. et al.**
Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. *J. Clin. Oncol.* 2006; vol 24: pp e20-e22.
160. **Bonini, C., Ferrari, G., Verzeletti, S. et al.**
HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. *Science* 1997; vol 276: pp 1719-1724.
161. **Bonini, C., Bondanza, A., Perna, S. K. et al.**
The suicide gene therapy challenge: how to improve a successful gene therapy approach. *Mol. Ther.* 2007; vol 15: pp 1248-1252.
162. **Berger, C., Flowers, M. E., Warren, E. H. et al.**
Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. *Blood* 2006; vol 107: pp 2294-2302.
163. **Traversari, C., Marktel, S., Magnani, Z. et al.**
The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. *Blood* 2007; vol 109: pp 4708-4715.
164. **Introna, M., Barbui, A. M., Bambacioni, F. et al.**
Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. *Hum. Gene Ther.* 2000; vol 11: pp 611-620.
165. **Serafini, M., Manganini, M., Borleri, G. et al.**
Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease. *Hum. Gene Ther.* 2004; vol 15: pp 63-76.
166. **Griffioen, M., van Egmond, H. M., Barnby-Porritt, H. et al.**
Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application. *Haematologica* 2008; vol 93: pp 1535-1543.
167. **van der Veken, L. T., Hagedoorn, R. S., van Loenen, M. M. et al.**
Alphabeta T-cell receptor engineered gammadelta T cells mediate effective antileukemic reactivity. *Cancer Res.* 2006; vol 66: pp 3331-3337.
168. **van der Veken, L. T., Coccors, M., Swart, E. et al.**
Alphabeta T cell receptor transfer to gammadelta T cells generates functional effector cells without mixed TCR dimers in vivo. *J. Immunol.* 2009; vol 182: pp 164-170.
169. **Day, E. K., Carmichael, A. J., ten Berge, I. et al.**
Rapid CD8+ T Cell Repertoire Focusing and Selection of High-Affinity Clones into Memory Following Primary Infection with a Persistent Human Virus: Human Cytomegalovirus. *J. Immunol.* 2007; vol 179: pp 3203-3213.
170. **Lehner, P. J., Wang, E. C., Moss, P. A. et al.**
Human HLA-A*0201-restricted cytotoxic T lymphocyte recognition of influenza A is dominated by T cells bearing the V beta 17 gene segment. *J. Exp. Med.* 1995; vol 181: pp 79-91.
171. **Moss, P. A., Moots, R. J., Rosenberg, W. M. et al.**
Extensive conservation of alpha and beta chains of the human T-cell antigen receptor recognizing HLA-A2 and influenza A matrix peptide. *Proc. Natl. Acad. Sci. U. S. A.* 1991; vol 88: pp 8987-8990.
172. **Silins, S. L., Cross, S. M., Krauer, K. G. et al.**
A functional link for major TCR expansions in healthy adults caused by persistent Epstein-Barr virus infection. *J. Clin. Invest* 1998; vol 102: pp 1551-1558.
173. **Teague, R. M., Greenberg, P. D., Fowler, C. et al.**
Peripheral CD8+ T cell tolerance to self-proteins is regulated proximally at the T cell receptor. *Immunity.* 2008; vol 28: pp 662-674.
174. **Burns, W. R., Zheng, Z., Rosenberg, S. A. et al.**
Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation. *Blood* 2009; vol 114: pp 2888-2899.
175. **Cooper, L. J., Topp, M. S., Pinzon, C. et al.**
Enhanced transgene expression in quiescent and activated human CD8+ T cells. *Hum. Gene Ther.* 2004; vol 15: pp 648-658.
176. **Plavec, I., Agarwal, M., Ho, K. E. et al.**
High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS. *Gene Ther.* 1997; vol 4: pp 128-139.
177. **Pollak, K. E., van Der Loo, J. C., Cooper, R. J. et al.**
Costimulation of transduced T lymphocytes via T cell receptor-CD3 complex and CD28 leads to increased transcription of integrated retrovirus. *Hum. Gene Ther.* 1999; vol 10: pp 2221-2236.
178. **Heemskerck, M. H., Hagedoorn, R. S., van der Hoorn, M. A. et al.**
Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. *Blood* 2007; vol 109: pp 235-243.
179. **Call, M. E. and Wucherpfennig, K. W.**
Molecular mechanisms for the assembly of the T cell receptor-CD3 complex. *Mol. Immunol.* 2004; vol 40: pp 1295-1305.
180. **Clevers, H., Alarcon, B., Wileman, T. et al.**
The T cell receptor/CD3 complex: a dynamic protein ensemble. *Annu. Rev. Immunol.* 1988; vol 6: pp 629-662.
181. **Koning, F., Maloy, W. L., Cohen, D. et al.**
Independent association of T cell receptor beta and gamma chains with CD3 in the same cell. *J. Exp. Med.* 1987; vol 166: pp 595-600.
182. **Bonifacino, J. S., Suzuki, C. K., Lippincott-Schwartz, J. et al.**
Pre-Golgi degradation of newly synthesized T-cell antigen receptor chains: intrinsic sensitivity and the role of subunit assembly. *J. Cell Biol.* 1989; vol 109: pp 73-83.
183. **Wileman, T., Carson, G. R., Concino, M. et al.**
The gamma and epsilon subunits of the CD3 complex inhibit pre-Golgi degradation of newly synthesized T cell antigen receptors. *J. Cell Biol.* 1990; vol 110: pp 973-986.
184. **Scholten, K. B., Kramer, D., Kueter, E. W. et al.**
Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. *Clin. Immunol.* 2006; vol 119: pp 135-145.
185. **Bialer, G., Horovitz-Fried, M., Ya'acobi, S. et al.**
Selected murine residues endow human TCR with enhanced tumor recognition. *J. Immunol.* 2010; vol 184: pp 6232-6241.
186. **Cohen, C. J., Zhao, Y., Zheng, Z. et al.**
Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. *Cancer Res.* 2006; vol 66: pp 8878-8886.

187. **Sommermeier, D. and Uckert, W.**
Minimal amino acid exchange in human TCR constant regions fosters improved function of TCR gene-modified T cells. *J. Immunol.* 2010; vol 184: pp 6223-6231.
188. **Cohen, C. J., Li, Y. F., El-Gamil, M. et al.**
Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. *Cancer Res.* 2007; vol 67: pp 3898-3903.
189. **Kuball, J., Dossett, M. L., Wolf, M. et al.**
Facilitating matched pairing and expression of TCR chains introduced into human T cells. *Blood* 2007; vol 109: pp 2331-2338.

CHAPTER 2 - RE-EXPRESSION

1. **Schumacher, T. N.**
T-cell-receptor gene therapy. *Nat. Rev. Immunol.* 2002; vol 2: pp 512-519.
2. **Clay, T. M., Custer, M. C., Sachs, J. et al.**
Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. *J. Immunol.* 1999; vol 163: pp 507-513.
3. **Cooper, L. J., Kalos, M., Lewinsohn, D. A. et al.**
Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. *J. Virol.* 2000; vol 74: pp 8207-8212.
4. **Dembic, Z., Haas, W., Weiss, S. et al.**
Transfer of specificity by murine alpha and beta T-cell receptor genes. *Nature* 1986; vol 320: pp 232-238.
5. **Heemskerck, M. H., Hoogeboom, M., de Paus, R. A. et al.**
Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. *Blood* 2003; vol 102: pp 3530-3540.
6. **Heemskerck, M. H., Hoogeboom, M., Hagedoorn, R. et al.**
Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. *J. Exp. Med.* 2004; vol 199: pp 885-894.
7. **Stanislowski, T., Voss, R. H., Lotz, C. et al.**
Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. *Nat. Immunol.* 2001; vol 2: pp 962-970.
8. **Johnson, L. A., Morgan, R. A., Dudley, M. E. et al.**
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. *Blood* 2009; vol 114: pp 535-546.
9. **Kessels, H. W., Wolkers, M. C., van, d. B. et al.**
Immunotherapy through TCR gene transfer. *Nat. Immunol.* 2001; vol 2: pp 957-961.
10. **Morgan, R. A., Dudley, M. E., Wunderlich, J. R. et al.**
Cancer regression in patients after transfer of genetically engineered lymphocytes. *Science* 2006; vol 314: pp 126-129.
11. **Xue, S. A., Gao, L., Hart, D. et al.**
Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. *Blood* 2005; vol 106: pp 3062-3067.
12. **Cooper, L. J., Topp, M. S., Pinzon, C. et al.**
Enhanced transgene expression in quiescent and activated human CD8+ T cells. *Hum. Gene Ther.* 2004; vol 15: pp 648-658.
13. **Plavec, I., Agarwal, M., Ho, K. E. et al.**
High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS. *Gene Ther.* 1997; vol 4: pp 128-139.
14. **Pollok, K. E., van Der Loo, J. C., Cooper, R. J. et al.**
Costimulation of transduced T lymphocytes via T cell receptor-CD3 complex and CD28 leads to increased transcription of integrated retrovirus. *Hum. Gene Ther.* 1999; vol 10: pp 2221-2236.
15. **Paillard, F., Sterkers, G., and Vaquero, C.**
Correlation between up-regulation of lymphokine mRNA and down-regulation of Tcr, CD4, CD8 and Ick mRNA as shown by the effect of CsA on activated T lymphocytes. *Biochem. Biophys. Res. Commun.* 1992; vol 186: pp 603-611.
16. **Paillard, F.**
Activation of retrovirally transduced T lymphocytes. *Hum. Gene Ther.* 1998; vol 9: pp 1395-1396.
17. **Lee, K. H., Dinner, A. R., Tu, C. et al.**
The immunological synapse balances T cell receptor signaling and degradation. *Science* 2003; vol 302: pp 1218-1222.
18. **Schonrich, G., Kalinke, U., Momburg, F. et al.**
Down-regulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction. *Cell* 1991; vol 65: pp 293-304.

19. **Schrum, A. G., Turka, L. A., and Palmer, E.**
Surface T-cell antigen receptor expression and availability for long-term antigenic signaling. *Immunol. Rev.* 2003; vol 196: pp 7-24.
20. **Viola, A. and Lanzavecchia, A.**
T cell activation determined by T cell receptor number and tunable thresholds. *Science* 1996; vol 273: pp 104-106.
21. **Andre, P., Boretto, J., Hueber, A. O. et al.**
A dominant-negative mutant of the Rab5 GTPase enhances T cell signaling by interfering with TCR down-modulation in transgenic mice. *J. Immunol.* 1997; vol 159: pp 5253-5263.
22. **Naramura, M., Jang, I. K., Kole, H. et al.**
c-Cbl and Cbl-b regulate T cell responsiveness by promoting ligand-induced TCR down-modulation. *Nat. Immunol.* 2002; vol 3: pp 1192-1199.
23. **Bronstein-Sitton, N., Wang, L., Cohen, L. et al.**
Expression of the T cell antigen receptor zeta chain following activation is controlled at distinct checkpoints. Implications for cell surface receptor down-modulation and re-expression. *J. Biol. Chem.* 1999; vol 274: pp 23659-23665.
24. **D'Oro, U., Vacchio, M. S., Weissman, A. M. et al.**
Activation of the Lck tyrosine kinase targets cell surface T cell antigen receptors for lysosomal degradation. *Immunity.* 1997; vol 7: pp 619-628.
25. **Valitutti, S., Muller, S., Salio, M. et al.**
Degradation of T cell receptor (TCR)-CD3-zeta complexes after antigenic stimulation. *J. Exp. Med.* 1997; vol 185: pp 1859-1864.
26. **Drake, D. R., III, Ream, R. M., Lawrence, C. W. et al.**
Transient loss of MHC class I tetramer binding after CD8+ T cell activation reflects altered T cell effector function. *J. Immunol.* 2005; vol 175: pp 1507-1515.
27. **Anikeeva, N., Somersalo, K., Sims, T. N. et al.**
Distinct role of lymphocyte function-associated antigen-1 in mediating effective cytolytic activity by cytotoxic T lymphocytes. *Proc. Natl. Acad. Sci. U. S. A* 2005; vol 102: pp 6437-6442.
28. **Green, J. M., Karpitskiy, V., Kimzey, S. L. et al.**
Coordinate regulation of T cell activation by CD2 and CD28. *J. Immunol.* 2000; vol 164: pp 3591-3595.
29. **Shaw, S., Luce, G. E., Quinones, R. et al.**
Two antigen-independent adhesion pathways used by human cytotoxic T-cell clones. *Nature* 1986; vol 323: pp 262-264.
30. **Call, M. E. and Wucherpfennig, K. W.**
Molecular mechanisms for the assembly of the T cell receptor-CD3 complex. *Mol. Immunol.* 2004; vol 40: pp 1295-1305.
31. **Clevers, H., Alarcon, B., Wileman, T. et al.**
The T cell receptor/CD3 complex: a dynamic protein ensemble. *Annu. Rev. Immunol.* 1988; vol 6: pp 629-662.
32. **Dietrich, J., Kastrup, J., Lauritsen, J. P. et al.**
TCRzeta is transported to and retained in the Golgi apparatus independently of other TCR chains: implications for TCR assembly. *Eur. J. Immunol.* 1999; vol 29: pp 1719-1728.
33. **Koning, F., Maloy, W. L., Cohen, D. et al.**
Independent association of T cell receptor beta and gamma chains with CD3 in the same cell. *J. Exp. Med.* 1987; vol 166: pp 595-600.
34. **Weissman, A. M., Frank, S. J., Orloff, D. G. et al.**
Role of the zeta chain in the expression of the T cell antigen receptor: genetic reconstitution studies. *EMBO J.* 1989; vol 8: pp 3651-3656.
35. **Bonifacio, J. S., Suzuki, C. K., Lippincott-Schwartz, J. et al.**
Pre-Golgi degradation of newly synthesized T-cell antigen receptor chains: intrinsic sensitivity and the role of subunit assembly. *J. Cell Biol.* 1989; vol 109: pp 73-83.
36. **Huppa, J. B. and Ploegh, H. L.**
The alpha chain of the T cell antigen receptor is degraded in the cytosol. *Immunity.* 1997; vol 7: pp 113-122.
37. **Wileman, T., Carson, G. R., Concino, M. et al.**
The gamma and epsilon subunits of the CD3 complex inhibit pre-Golgi degradation of newly synthesized T cell antigen receptors. *J. Cell Biol.* 1990; vol 110: pp 973-986.
38. **Rubin, B., Llobera, R., Gouaillard, C. et al.**
Dissection of the role of CD3gamma chains in profound but reversible T-cell receptor down-regulation. *Scand. J. Immunol.* 2000; vol 52: pp 173-183.
39. **Brower, R. C., England, R., Takeshita, T. et al.**
Minimal requirements for peptide mediated activation of CD8+ CTL. *Mol. Immunol.* 1994; vol 31: pp 1285-1293.
40. **Demotz, S., Grey, H. M., and Sette, A.**
The minimal number of class II MHC-antigen complexes needed for T cell activation. *Science* 1990; vol 249: pp 1028-1030.
41. **Harding, C. V. and Unanue, E. R.**
Quantitation of antigen-presenting cell MHC class II/peptide complexes necessary for T-cell stimulation. *Nature* 1990; vol 346: pp 574-576.
42. **Sykulev, Y., Joo, M., Vturina, I. et al.**
Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. *Immunity.* 1996; vol 4: pp 565-571.
43. **Demotte, N., Colau, D., Ottaviani, S. et al.**
A reversible functional defect of CD8+ T lymphocytes involving loss of tetramer labeling. *Eur. J. Immunol.* 2002; vol 32: pp 1688-1697.
44. **Demotte, N., Stroobant, V., Courtoy, P. J. et al.**
Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. *Immunity.* 2008; vol 28: pp 414-424.
45. **Bonefeld, C. M., Rasmussen, A. B., Lauritsen, J. P. et al.**
TCR comodulation of nonengaged TCR takes place by a protein kinase C and CD3 gamma di-leucine-based motif-dependent mechanism. *J. Immunol.* 2003; vol 171: pp 3003-3009.
46. **Exley, M., Wileman, T., Mueller, B. et al.**
Evidence for multivalent structure of T-cell antigen receptor complex. *Mol. Immunol.* 1995; vol 32: pp 829-839.
47. **Niedergang, F., Dautry-Varsat, A., and Alcover, A.**
Peptide antigen or superantigen-induced down-regulation of TCRs involves both stimulated and unstimulated receptors. *J. Immunol.* 1997; vol 159: pp 1703-1710.

48. **San Jose, E., Borroto, A., Niedergang, F. et al.**
Triggering the TCR complex causes the downregulation of nonengaged receptors by a signal transduction-dependent mechanism. *Immunity*. 2000; vol 12: pp 161-170.
49. **Stotz, S. H., Bolliger, L., Carbone, F. R. et al.**
T cell receptor (TCR) antagonism without a negative signal: evidence from T cell hybridomas expressing two independent TCRs. *J. Exp. Med.* 1999; vol 189: pp 253-264.
50. **Valitutti, S., Muller, S., Cella, M. et al.**
Serial triggering of many T-cell receptors by a few peptide-MHC complexes. *Nature* 1995; vol 375: pp 148-151.
51. **Burns, W. R., Zheng, Z., Rosenberg, S. A. et al.**
Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation. *Blood* 2009; vol 114: pp 2888-2899.
52. **Pule, M. A., Savoldo, B., Myers, G. D. et al.**
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. *Nat. Med.* 2008; vol 14: pp 1264-1270.
53. **van Loenen, M. M., Hagedoorn, R. S., Kester, M. G. et al.**
Kinetic preservation of dual specificity of coprogrammed minor histocompatibility antigen-reactive virus-specific T cells. *Cancer Res.* 2009; vol 69: pp 2034-2041.
54. **Ruggieri, L., Aiuti, A., Salomoni, M. et al.**
Cell-surface marking of CD(34+)-restricted phenotypes of human hematopoietic progenitor cells by retrovirus-mediated gene transfer. *Hum. Gene Ther.* 1997; vol 8: pp 1611-1623.
55. **Kinsella, T. M. and Nolan, G. P.**
Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. *Hum. Gene Ther.* 1996; vol 7: pp 1405-1413.
56. **Burrows, S. R., Kienzle, N., Winterhalter, A. et al.**
Peptide-MHC class I tetrameric complexes display exquisite ligand specificity. *J. Immunol.* 2000; vol 165: pp 6229-6234.
57. **Heemskerk, M. H., Blom, B., Nolan, G. et al.**
Inhibition of T cell and promotion of natural killer cell development by the dominant negative helix loop helix factor Id3. *J. Exp. Med.* 1997; vol 186: pp 1597-1602.
58. **van der Veken, L. T., Hagedoorn, R. S., van Loenen, M. M. et al.**
Alphabeta T-cell receptor engineered gammadelta T cells mediate effective antileukemic reactivity. *Cancer Res.* 2006; vol 66: pp 3331-3337.

CHAPTER 3 - MINOR HISTOCOMPATIBILITY

1. **Collins, R. H., Jr., Shpilberg, O., Drobyski, W. R. et al.**
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. *J. Clin. Oncol.* 1997; vol 15: pp 433-444.
2. **Kolb, H. J. and Holler, E.**
Adoptive immunotherapy with donor lymphocyte transfusions. *Curr. Opin. Oncol.* 1997; vol 9: pp 139-145.
3. **Kircher, B., Stevanovic, S., Urbanek, M. et al.**
Induction of HA-1-specific cytotoxic T-cell clones parallels the therapeutic effect of donor lymphocyte infusion. *Br. J. Haematol.* 2002; vol 117: pp 935-939.
4. **Kloosterboer, F. M., van Luxemburg-Heijs, S. A., van Soest, R. A. et al.**
Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells. *Leukemia* 2004; vol 18: pp 798-808.
5. **Marijt, W. A., Heemskerk, M. H., Kloosterboer, F. M. et al.**
Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. *Proc. Natl. Acad. Sci. U. S. A* 2003; vol 100: pp 2742-2747.
6. **de Bueger, M., Bakker, A., van Rood, J. J. et al.**
Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. *J. Immunol.* 1992; vol 149: pp 1788-1794.
7. **Dolstra, H., Fredrix, H., Maas, F. et al.**
A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. *J. Exp. Med.* 1999; vol 189: pp 301-308.
8. **Clay, T. M., Custer, M. C., Sachs, J. et al.**
Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. *J. Immunol.* 1999; vol 163: pp 507-513.
9. **Cooper, L. J., Kalos, M., Lewinsohn, D. A. et al.**
Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. *J. Virol.* 2000; vol 74: pp 8207-8212.

10. **Dembic, Z., Haas, W., Weiss, S. et al.**
Transfer of specificity by murine alpha and beta T-cell receptor genes. *Nature* 1986; vol 320: pp 232-238.
11. **Heemskerk, M. H., Hoogboom, M., de Paus, R. A. et al.**
Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. *Blood* 2003; vol 102: pp 3530-3540.
12. **Stanislowski, T., Voss, R. H., Lotz, C. et al.**
Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. *Nat. Immunol.* 2001; vol 2: pp 962-970.
13. **Kessels, H. W., Wolkers, M. C., van, d. B. et al.**
Immunotherapy through TCR gene transfer. *Nat. Immunol.* 2001; vol 2: pp 957-961.
14. **Morgan, R. A., Dudley, M. E., Wunderlich, J. R. et al.**
Cancer regression in patients after transfer of genetically engineered lymphocytes. *Science* 2006; vol 314: pp 126-129.
15. **Xue, S. A., Gao, L., Hart, D. et al.**
Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. *Blood* 2005; vol 106: pp 3062-3067.
16. **Heemskerk, M. H., Hoogboom, M., Hagedoorn, R. et al.**
Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. *J. Exp. Med.* 2004; vol 199: pp 885-894.
17. **Day, E. K., Carmichael, A. J., ten Berge, I. et al.**
Rapid CD8+ T Cell Repertoire Focusing and Selection of High-Affinity Clones into Memory Following Primary Infection with a Persistent Human Virus: Human Cytomegalovirus. *J. Immunol.* 2007; vol 179: pp 3203-3213.
18. **Lehner, P. J., Wang, E. C., Moss, P. A. et al.**
Human HLA-A*0201-restricted cytotoxic T lymphocyte recognition of influenza A is dominated by T cells bearing the V beta 17 gene segment. *J. Exp. Med.* 1995; vol 181: pp 79-91.
19. **Moss, P. A., Moots, R. J., Rosenberg, W. M. et al.**
Extensive conservation of alpha and beta chains of the human T-cell antigen receptor recognizing HLA-A2 and influenza A matrix peptide. *Proc. Natl. Acad. Sci. U. S. A* 1991; vol 88: pp 8987-8990.
20. **Silins, S. L., Cross, S. M., Krauer, K. G. et al.**
A functional link for major TCR expansions in healthy adults caused by persistent Epstein-Barr virus infection. *J. Clin. Invest* 1998; vol 102: pp 1551-1558.
21. **Trautmann, L., Rimbart, M., Echasserieu, K. et al.**
Selection of T cell clones expressing high-affinity public TCRs within Human cytomegalovirus-specific CD8 T cell responses. *J. Immunol.* 2005; vol 175: pp 6123-6132.
22. **Einsele, H., Roosnek, E., Rufer, N. et al.**
Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. *Blood* 2002; vol 99: pp 3916-3922.
23. **Peggs, K. S., Verfuert, S., Pizzey, A. et al.**
Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. *Lancet* 2003; vol 362: pp 1375-1377.
24. **Walter, E. A., Greenberg, P. D., Gilbert, M. J. et al.**
Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. *N. Engl. J. Med.* 1995; vol 333: pp 1038-1044.
25. **Teague, R. M., Greenberg, P. D., Fowler, C. et al.**
Peripheral CD8+ T cell tolerance to self-proteins is regulated proximally at the T cell receptor. *Immunity.* 2008; vol 28: pp 662-674.
26. **Hofmann, M., Radsak, M., Rechtsteiner, G. et al.**
T cell avidity determines the level of CTL activation. *Eur. J. Immunol.* 2004; vol 34: pp 1798-1806.
27. **Tskvitarva-Fuller, I., Rozelle, A. L., Yin, H. L. et al.**
Regulation of sustained actin dynamics by the TCR and costimulation as a mechanism of receptor localization. *J. Immunol.* 2003; vol 171: pp 2287-2295.
28. **Ruggieri, L., Aiuti, A., Salomoni, M. et al.**
Cell-surface marking of CD(34+)-restricted phenotypes of human hematopoietic progenitor cells by retrovirus-mediated gene transfer. *Hum. Gene Ther.* 1997; vol 8: pp 1611-1623.
29. **Burrows, S. R., Kienzle, N., Winterhalter, A. et al.**
Peptide-MHC class I tetrameric complexes display exquisite ligand specificity. *J. Immunol.* 2000; vol 165: pp 6229-6234.
30. **Hanenberg, H., Xiao, X. L., Dilloo, D. et al.**
Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. *Nat. Med.* 1996; vol 2: pp 876-882.
31. **Heemskerk, M. H., Blom, B., Nolan, G. et al.**
Inhibition of T cell and promotion of natural killer cell development by the dominant negative helix loop helix factor Id3. *J. Exp. Med.* 1997; vol 186: pp 1597-1602.
32. **Savage, P., Millrain, M., Dimakou, S. et al.**
Expansion of CD8+ cytotoxic T cells in vitro and in vivo using MHC class I tetramers. *Tumour. Biol.* 2007; vol 28: pp 70-76.
33. **Fahmy, T. M., Bieler, J. G., Edidin, M. et al.**
Increased TCR avidity after T cell activation: a mechanism for sensing low-density antigen. *Immunity.* 2001; vol 14: pp 135-143.
34. **Mamalaki, C., Norton, T., Tanaka, Y. et al.**
Thymic depletion and peripheral activation of class I major histocompatibility complex-restricted T cells by soluble peptide in T-cell receptor transgenic mice. *Proc. Natl. Acad. Sci. U. S. A* 1992; vol 89: pp 11342-11346.
35. **Schrum, A. G., Wells, A. D., and Turka, L. A.**
Enhanced surface TCR replenishment mediated by CD28 leads to greater TCR engagement during primary stimulation. *Int. Immunol.* 2000; vol 12: pp 833-842.
36. **Wong, P. and Pamer, E. G.**
Feedback regulation of pathogen-specific T cell priming. *Immunity.* 2003; vol 18: pp 499-511.
37. **Anton van der, M. P., Davis, S. J., Shaw, A. S. et al.**
Cytoskeletal polarization and redistribution of cell-surface molecules during T cell antigen recognition. *Semin. Immunol.* 2000; vol 12: pp 5-21.
38. **Grakoui, A., Bromley, S. K., Sumen, C. et al.**
The immunological synapse: a molecular machine controlling T cell activation. *Science* 1999; vol 285: pp 221-227.
39. **Addo, M. M. and Rosenberg, E. S.**
Cellular immune responses in transplantation-associated chronic viral infections. *Transpl. Infect. Dis.* 2002; vol 4: pp 31-40.

40. **Hislop, A. D., Gudgeon, N. H., Callan, M. F. et al.**
EBV-specific CD8+ T cell memory: relationships between epitope specificity, cell phenotype, and immediate effector function. *J. Immunol.* 2001; vol 167: pp 2019-2029.
41. **van Leeuwen, E. M., de Bree, G. J., Ten, B., I et al.**
Human virus-specific CD8+ T cells: diversity specialists. *Immunol. Rev.* 2006; vol 211: pp 225-235.
42. **Berger, C., Jensen, M. C., Lansdorf, P. M. et al.**
Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. *J. Clin. Invest* 2008; vol 118: pp 294-305.
43. **Lefrancois, L.**
Development, trafficking, and function of memory T-cell subsets. *Immunol. Rev.* 2006; vol 211: pp 93-103.
44. **Hasegawa, A., Moriya, C., Liu, H. et al.**
Analysis of TCRalphabeta combinations used by simian immunodeficiency virus-specific CD8+ T cells in rhesus monkeys: implications for CTL immunodominance. *J. Immunol.* 2007; vol 178: pp 3409-3417.
45. **Appay, V., Dunbar, P. R., Callan, M. et al.**
Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. *Nat. Med.* 2002; vol 8: pp 379-385.
46. **Appay, V., van Lier, R. A., Sallusto, F. et al.**
Phenotype and function of human T lymphocyte subsets: Consensus and issues. *Cytometry A* 2008; vol
47. **Gamadia, L. E., van Leeuwen, E. M., Remmerswaal, E. B. et al.**
The size and phenotype of virus-specific T cell populations is determined by repetitive antigenic stimulation and environmental cytokines. *J. Immunol.* 2004; vol 172: pp 6107-6114.

CHAPTER 4 - MIXED DIMERS

1. **Collins, R. H., Jr., Shpilberg, O., Drobyski, W. R. et al.**
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. *J. Clin. Oncol.* 1997; vol 15: pp 433-444.
2. **Kolb, H. J., Mittermuller, J., Clemm, C. et al.**
Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. *Blood* 1990; vol 76: pp 2462-2465.
3. **Dudley, M. E., Yang, J. C., Sherry, R. et al.**
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. *J. Clin. Oncol.* 2008; vol 26: pp 5233-5239.
4. **Clay, T. M., Custer, M. C., Sachs, J. et al.**
Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. *J. Immunol.* 1999; vol 163: pp 507-513.
5. **Cooper, L. J., Kalos, M., Lewinsohn, D. A. et al.**
Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. *J. Virol.* 2000; vol 74: pp 8207-8212.
6. **Dembic, Z., Haas, W., Weiss, S. et al.**
Transfer of specificity by murine alpha and beta T-cell receptor genes. *Nature* 1986; vol 320: pp 232-238.
7. **Heemskerk, M. H., Hoogeboom, M., de Paus, R. A. et al.**
Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. *Blood* 2003; vol 102: pp 3530-3540.
8. **Heemskerk, M. H., Hoogeboom, M., Hagedoorn, R. et al.**
Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. *J. Exp. Med.* 2004; vol 199: pp 885-894.
9. **Kessels, H. W., Wolkers, M. C., van, d. B. et al.**
Immunotherapy through TCR gene transfer. *Nat. Immunol.* 2001; vol 2: pp 957-961.
10. **Morgan, R. A., Dudley, M. E., Wunderlich, J. R. et al.**
Cancer regression in patients after transfer of genetically engineered lymphocytes. *Science* 2006; vol 314: pp 126-129.
11. **Xue, S. A., Gao, L., Hart, D. et al.**
Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. *Blood* 2005; vol 106: pp 3062-3067.
12. **Johnson, L. A., Morgan, R. A., Dudley, M. E. et al.**
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. *Blood* 2009; vol 114: pp 535-546.
13. **Heemskerk, M. H., Hagedoorn, R. S., van der Hoorn, M. A. et al.**
Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. *Blood* 2007; vol 109: pp 235-243.
14. **Cohen, C. J., Zhao, Y., Zheng, Z. et al.**
Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. *Cancer Res.* 2006; vol 66: pp 8878-8886.
15. **Voss, R. H., Kuball, J., Engel, R. et al.**
Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression. *Immunol. Res.* 2006; vol 34: pp 67-87.
16. **Cohen, C. J., Li, Y. F., El-Gamil, M. et al.**
Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. *Cancer Res.* 2007; vol 67: pp 3898-3903.
17. **Kuball, J., Dossett, M. L., Wolf, M. et al.**
Facilitating matched pairing and expression of TCR chains introduced into human T cells. *Blood* 2007; vol 109: pp 2331-2338.
18. **Schumacher, T. N.**
T-cell-receptor gene therapy. *Nat. Rev. Immunol.* 2002; vol 2: pp 512-519.

19. **van der Veken, L. T., Hagedoorn, R. S., van Loenen, M. M. et al.**
Alphabeta T-cell receptor engineered gammadelta T cells mediate effective antileukemic reactivity. *Cancer Res.* 2006; vol 66: pp 3331-3337.
20. **Amir, A. L., D'Orsogna, L. J., Roelen, D. L. et al.**
Allo-HLA reactivity of virus-specific memory T cells is common. *Blood* 2010; vol 115: pp 3146-3157.
21. **Hart, D. P., Xue, S. A., Thomas, S. et al.**
Retroviral transfer of a dominant TCR prevents surface expression of a large proportion of the endogenous TCR repertoire in human T cells. *Gene Ther.* 2008; vol 15: pp 625-631.
22. **Bendle, G. M., Haanen, J. B., and Schumacher, T. N.**
Preclinical development of T cell receptor gene therapy. *Curr. Opin. Immunol.* 2009; vol 21: pp 209-214.
23. **Szymczak, A. L., Workman, C. J., Wang, Y. et al.**
Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. *Nat. Biotechnol.* 2004; vol 22: pp 589-594.
24. **van der Veken, L. T., Coccoris, M., Swart, E. et al.**
Alphabeta T cell receptor transfer to gammadelta T cells generates functional effector cells without mixed TCR dimers in vivo. *J. Immunol.* 2009; vol 182: pp 164-170.
25. **Day, E. K., Carmichael, A. J., ten Berge, I. et al.**
Rapid CD8+ T Cell Repertoire Focusing and Selection of High-Affinity Clones into Memory Following Primary Infection with a Persistent Human Virus: Human Cytomegalovirus. *J. Immunol.* 2007; vol 179: pp 3203-3213.
26. **Silins, S. L., Cross, S. M., Krauer, K. G. et al.**
A functional link for major TCR expansions in healthy adults caused by persistent Epstein-Barr virus infection. *J. Clin. Invest* 1998; vol 102: pp 1551-1558.
27. **Heemskerk, M. H., Blom, B., Nolan, G. et al.**
Inhibition of T cell and promotion of natural killer cell development by the dominant negative helix loop helix factor Id3. *J. Exp. Med.* 1997; vol 186: pp 1597-1602.
28. **Burrows, S. R., Kienle, N., Winterhalter, A. et al.**
Peptide-MHC class I tetrameric complexes display exquisite ligand specificity. *J. Immunol.* 2000; vol 165: pp 6229-6234.
29. **Jedema, I., van der Werff, N. M., Barge, R. M. et al.**
New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. *Blood* 2004; vol 103: pp 2677-2682.

CHAPTER 5 - HA-1

1. **Collins, R. H., Jr., Shpilberg, O., Drobyski, W. R. et al.**
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. *J. Clin. Oncol.* 1997; vol 15: pp 433-444.
2. **Kolb, H. J., Mittermuller, J., Clemm, C. et al.**
Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. *Blood* 1990; vol 76: pp 2462-2465.
3. **Marijt, W. A., Kernan, N. A., az-Barrientos, T. et al.**
Multiple minor histocompatibility antigen-specific cytotoxic T lymphocyte clones can be generated during graft rejection after HLA-identical bone marrow transplantation. *Bone Marrow Transplant.* 1995; vol 16: pp 125-132.
4. **Marijt, W. A., Heemskerk, M. H., Kloosterboer, F. M. et al.**
Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. *Proc. Natl. Acad. Sci. U. S. A.* 2003; vol 100: pp 2742-2747.
5. **Falkenburg, J. H., Smit, W. M., and Willemze, R.**
Cytotoxic T-lymphocyte (CTL) responses against acute or chronic myeloid leukemia. *Immunol. Rev.* 1997; vol 157: pp 223-230.
6. **de Bueger, M., Bakker, A., van Rood, J. J. et al.**
Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. *J. Immunol.* 1992; vol 149: pp 1788-1794.
7. **Klein, C. A., Wilke, M., Pool, J. et al.**
The hematopoietic system-specific minor histocompatibility antigen HA-1 shows aberrant expression in epithelial cancer cells. *J. Exp. Med.* 2002; vol 196: pp 359-368.
8. **den Haan, J. M., Sherman, N. E., Blokland, E. et al.**
Identification of a graft versus host disease-associated human minor histocompatibility antigen. *Science* 1995; vol 268: pp 1476-1480.
9. **Spierings, E., Hendriks, M., Absi, L. et al.**
Phenotype frequencies of autosomal minor histocompatibility antigens display significant differences among populations. *PLoS. Genet.* 2007; vol 3: pp e103

10. **Kloosterboer, F. M., van Luxemburg-Heijs, S. A., van Soest, R. A. et al.**
Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells. *Leukemia* 2004; vol 18: pp 798-808.
11. **Heemskerck, M. H., Hoogeboom, M., de Paus, R. A. et al.**
Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. *Blood* 2003; vol 102: pp 3530-3540.
12. **Mommaas, B., van Halteren, A. G., Pool, J. et al.**
Adult and cord blood T cells can acquire HA-1 specific-ity through HA-1 T-cell receptor gene transfer. *Haematologica* 2005; vol 90: pp 1415-1421.
13. **Griffioen, M., van Egmund, H. M., Barnby-Porritt, H. et al.**
Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application. *Haematologica* 2008; vol 93: pp 1535-1543.
14. **Verdijk, R. M., Mutis, T., Wilke, M. et al.**
Exclusive TCRVbeta chain usage of ex vivo generated minor Histo-compatibility antigen HA-1 specific cytotoxic T cells: implications for monitoring of immunotherapy of leukemia by TCRBV spectratyping. *Hematol. J.* 2002; vol 3: pp 271-275.
15. **Goulmy, E., Pool, J., and van den Elsen, P. J.**
Interindividual conservation of T-cell receptor beta chain variable regions by minor histocompatibility antigen-specific HLA-A*0201-restricted cytotoxic T-cell clones. *Blood* 1995; vol 85: pp 2478-2481.
16. **Scholten, K. B., Kramer, D., Kueter, E. W. et al.**
Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. *Clin. Immunol.* 2006; vol 119: pp 135-145.
17. **Boulter, J. M., Glick, M., Todorov, P. T. et al.**
Stable, soluble T-cell receptor molecules for crys-tallization and therapeutics. *Protein Eng* 2003; vol 16: pp 707-711.
18. **Cohen, C. J., Li, Y. F., El-Gamil, M. et al.**
Enhanced antitumor activity of T cells engineered to ex-press T-cell receptors with a second disulfide bond. *Cancer Res.* 2007; vol 67: pp 3898-3903.
19. **Kuball, J., Dossett, M. L., Wolff, M. et al.**
Facilitating matched pairing and expression of TCR chains introduced into human T cells. *Blood* 2007; vol 109: pp 2331-2338.
20. **van der Veken, L. T., Hoogeboom, M., de Paus, R. A. et al.**
HLA class II restricted T-cell receptor gene transfer generates CD4+ T cells with helper activity as well as cytotoxic capacity. *Gene Ther.* 2005; vol 12: pp 1686-1695.
21. **Zhang, G., Gurtu, V., and Kain, S. R.**
An enhanced green fluorescent protein allows sensi-tive detection of gene transfer in mammalian cells. *Biochem. Biophys. Res. Commun.* 1996; vol 227: pp 707-711.
22. **Ruggieri, L., Aiuti, A., Salomoni, M. et al.**
Cell-surface marking of CD(34+)-restricted phenotypes of human hematopoietic progenitor cells by retrovirus-mediated gene transfer. *Hum. Gene Ther.* 1997; vol 8: pp 1611-1623.
23. **Szymczak, A. L., Workman, C. J., Wang, Y. et al.**
Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. *Nat. Biotechnol.* 2004; vol 22: pp 589-594.
24. **Baum, C., Hegewisch-Becker, S., Eckert, H. G. et al.**
Novel retroviral vectors for efficient expression of the multid-rug resistance (mdr-1) gene in early hematopoietic cells. *J. Virol.* 1995; vol 69: pp 7541-7547.
25. **Hildinger, M., Abel, K. L., Ostertag, W. et al.**
Design of 5' untranslated sequences in retrovi-ral vectors developed for medical use. *J. Virol.* 1999; vol 73: pp 4083-4089.
26. **Kinsella, T. M. and Nolan, G. P.**
Episomal vectors rapidly and stably pro-duce high-titer recombinant retrovirus. *Hum. Gene Ther.* 1996; vol 7: pp 1405-1413.
27. **Heemskerck, M. H., Blom, B., Nolan, G. et al.**
Inhibition of T cell and promotion of natural killer cell develop-ment by the dominant negative helix loop helix factor Id3. *J. Exp. Med.* 1997; vol 186: pp 1597-1602.
28. **Burrows, S. R., Kienzle, N., Winterhalter, A. et al.**
Peptide-MHC class I tetrameric complexes dis-play exquisite ligand specificity. *J. Immunol.* 2000; vol 165: pp 6229-6234.
29. **van der Veken, L. T., Hagedoorn, R. S., van Loenen, M. M. et al.**
Alphabeta T-cell receptor engineered gammadelta T cells mediate effective antileukemic reactivity. *Cancer Res.* 2006; vol 66: pp 3331-3337.
30. **Heemskerck, M. H., Hagedoorn, R. S., van der Hoorn, M. A. et al.**
Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. *Blood* 2007; vol 109: pp 235-243.
31. **Hanenberg, H., Xiao, X. L., Dilloo, D. et al.**
Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. *Nat. Med.* 1996; vol 2: pp 876-882.
32. **Heemskerck, M. H., Hagedoorn, R. S., van der Hoorn, M. A. et al.**
Efficiency of T cell receptor expression in dual specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. *Blood* 2006; vol
33. **van Loenen, M. M., de Boer, R., Amir, A. L. et al.**
Mixed T cell receptor dimers harbor potentially harmful neoreactivity. *Proc. Natl. Acad. Sci. U. S. A* 2010; vol 107: pp 10972-10977.
34. **Engels, B., Cam, H., Schuler, T. et al.**
Retroviral vectors for high-level transgene expression in T lymphocytes. *Hum. Gene Ther.* 2003; vol 14: pp 1155-1168.
35. **Hart, D. P., Xue, S. A., Thomas, S. et al.**
Retroviral transfer of a dominant TCR prevents surface expression of a large proportion of the endogenous TCR repertoire in human T cells. *Gene Ther.* 2008; vol 15: pp 625-631.
36. **Heemskerck, M. H., Hoogeboom, M., Hagedoorn, R. et al.**
Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. *J. Exp. Med.* 2004; vol 199: pp 885-894.

37. **Kloosterboer, F. M., van Luxemburg-Heijs, S. A., van Soest, R. A. et al.**

Minor histocompatibility antigen-specific T cells with multiple distinct specificities can be isolated by direct cloning of IFN γ -secreting T cells from patients with relapsed leukemia responding to donor lymphocyte infusion. *Leukemia* 2005; vol 19: pp 83-90.

SUPPORTING INFORMATION

1. **Heemskerck MH et al.**
Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. *Blood* 2003; vol 102: pp 3530-3540.
2. **Heemskerck MH et al.**
Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD $_3$ complex. *Blood* 2007; vol 109: pp 235-243.
3. **Hoogendoorn M et al.**
Generation of B-cell chronic lymphocytic leukemia (B-CLL)-reactive T-cell lines and clones from HLA class I-matched donors using modified B-CLL cells as stimulators: implications for adoptive immunotherapy. *Leukemia* 2004; vol 18: pp 1278-1287.
4. **Griffioen M et al.**
Identification of phosphatidylinositol 4-kinase type II beta as HLA class II-restricted target in graft versus leukemia reactivity. *Proc Natl Acad Sci U S A* 2008; vol 105: pp 3837-3842.

CHAPTER 6 - SUMMARY AND DISCUSSION

1. **de Bueger, M., Bakker, A., van Rood, J. J. et al.**
Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. *J. Immunol.* 1992; vol 149: pp 1788-1794.
2. **Klein, C. A., Wilke, M., Pool, J. et al.**
The hematopoietic system-specific minor histocompatibility antigen HA-1 shows aberrant expression in epithelial cancer cells. *J. Exp. Med.* 2002; vol 196: pp 359-368.
3. **Pierce, R. A., Field, E. D., Mutis, T. et al.**
The HA-2 minor histocompatibility antigen is derived from a diallelic gene encoding a novel human class I myosin protein. *J. Immunol.* 2001; vol 167: pp 3223-3230.
4. **den Haan, J. M., Meadows, L. M., Wang, W. et al.**
The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. *Science* 1998; vol 279: pp 1054-1057.
5. **Spierings, E., Hendriks, M., Absi, L. et al.**
Phenotype frequencies of autosomal minor histocompatibility antigens display significant differences among populations. *PLoS. Genet.* 2007; vol 3: pp e103
6. **van Els, C. A., D'Amaro, J., Pool, J. et al.**
Immunogenetics of human minor histocompatibility antigens: their polymorphism and immunodominance. *Immunogenetics* 1992; vol 35: pp 161-165.
7. **Pietz, B. C., Warden, M. B., Duchateau, B. K. et al.**
Multiplex genotyping of human minor histocompatibility antigens. *Hum. Immunol.* 2005; vol 66: pp 1174-1182.
8. **Hart, D. P., Xue, S. A., Thomas, S. et al.**
Retroviral transfer of a dominant TCR prevents surface expression of a large proportion of the endogenous TCR repertoire in human T cells. *Gene Ther.* 2008; vol 15: pp 625-631.
9. **Heemskerck, M. H., Hagedoorn, R. S., van der Hoorn, M. A. et al.**
Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD $_3$ complex. *Blood* 2007; vol 109: pp 235-243.
10. **Sommermeier, D., Neudorfer, J., Weinhold, M. et al.**
Designer T cells by T cell receptor replacement. *Eur. J. Immunol.* 2006; vol 36: pp 3052-3059.
11. **Mommaas, B., van Halteren, A. G., Pool, J. et al.**
Adult and cord blood T cells can acquire HA-1 specificity through HA-1 T-cell receptor gene transfer. *Haematologica* 2005; vol 90: pp 1415-1421.
12. **Griffioen, M., van Egmond, H. M., Barnby-Porritt, H. et al.**
Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application. *Haematologica* 2008; vol 93: pp 1535-1543.
13. **Scholten, K. B., Kramer, D., Kueter, E. W. et al.**
Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. *Clin. Immunol.* 2006; vol 119: pp 135-145.
14. **Azuma, T., Makita, M., Ninomiya, K. et al.**
Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes. *Br. J. Haematol.* 2002; vol 116: pp 601-603.
15. **Gao, L., Bellantuono, I., Elsassser, A. et al.**
Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. *Blood* 2000; vol 95: pp 2198-2203.
16. **Ohnami, H., Yasukawa, M., and Fujita, S.**
HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. *Blood* 2000; vol 95: pp 286-293.
17. **Oka, Y., Elisseeva, O. A., Tsuboi, A. et al.**
Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. *Immunogenetics* 2000; vol 51: pp 99-107.
18. **Rezvani, K., Grube, M., Brenchley, J. M. et al.**
Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. *Blood* 2003; vol 102: pp 2892-2900.
19. **Scheibenbogen, C., Letsch, A., Thiel, E. et al.**
CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. *Blood* 2002; vol 100: pp 2132-2137.

20. **Moldrem, J. J., Clave, E., Jiang, Y. Z. et al.**
Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. *Blood* 1997; vol 90: pp 2529-2534.
21. **Moldrem, J. J., Lee, P. P., Wang, C. et al.**
A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. *Cancer Res.* 1999; vol 59: pp 2675-2681.
22. **Moldrem, J. J., Lee, P. P., Kant, S. et al.**
Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. *J. Clin. Invest* 2003; vol 111: pp 639-647.
23. **Kisielow, P., Bluthmann, H., Staerz, U. D. et al.**
Tolerance in T-cell-receptor transgenic mice involves deletion of nonmature CD4+8+ thymocytes. *Nature* 1988; vol 333: pp 742-746.
24. **Offringa, R.**
Antigen choice in adoptive T-cell therapy of cancer. *Curr. Opin. Immunol.* 2009; vol 21: pp 190-199.
25. **Savage, P., Gao, L., Vento, K. et al.**
Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen. *Blood* 2004; vol 103: pp 4613-4615.
26. **Wilde, S., Sommermeyer, D., Frankenberger, B. et al.**
Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity. *Blood* 2009; vol 114: pp 2131-2139.
27. **Falkenburg, W. J. J., Melenhorst, J. J., Kester, M. G. D. et al.**
Allogeneic HLA-A2-Restricted WT1-Specific T Cells From Mismatched Donors Are Highly Reactive but Show Potentially Hazardous Promiscuity. *ASH Annual Meeting Abstracts* 2009; vol 114: pp 4081
28. **Johnson, L. A., Morgan, R. A., Dudley, M. E. et al.**
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. *Blood* 2009; vol 114: pp 535-546.
29. **Lamers, C. H., Sleijfer, S., Vulto, A. G. et al.**
Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. *J. Clin. Oncol.* 2006; vol 24: pp e20-e22.
30. **Morgan, R. A., Yang, J. C., Kitano, M. et al.**
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. *Mol. Ther.* 2010; vol 18: pp 843-851.
31. **Heslop, H. E.**
Safer CARs. *Mol. Ther.* 2010; vol 18: pp 661-662.
32. **Chervin, A. S., Aggen, D. H., Raseman, J. M. et al.**
Engineering higher affinity T cell receptors using a T cell display system. *J. Immunol. Methods* 2008; vol 339: pp 175-184.
33. **Holler, P. D., Holman, P. O., Shusta, E. V. et al.**
In vitro evolution of a T cell receptor with high affinity for peptide/MHC. *Proc. Natl. Acad. Sci. U. S. A* 2000; vol 97: pp 5387-5392.
34. **Kessels, H. W., van, d. B., Spits, H. et al.**
Changing T cell specificity by retroviral T cell receptor display. *Proc. Natl. Acad. Sci. U. S. A* 2000; vol 97: pp 14578-14583.
35. **Robbins, P. F., Li, Y. F., El-Gamil, M. et al.**
Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. *J. Immunol.* 2008; vol 180: pp 6116-6131.
36. **Varela-Rohena, A., Molloy, P. E., Dunn, S. M. et al.**
Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. *Nat. Med.* 2008; vol 14: pp 1390-1395.
37. **Zhao, Y., Bennett, A. D., Zheng, Z. et al.**
High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines. *J. Immunol.* 2007; vol 179: pp 5845-5854.
38. **Heemskerck, M. H., Hoogeboom, M., de Paus, R. A. et al.**
Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. *Blood* 2003; vol 102: pp 3530-3540.
39. **Schmid, D. A., Irving, M. B., Posevitz, V. et al.**
Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. *J. Immunol.* 2010; vol 184: pp 4936-4946.
40. **Bollard, C. M., Gottschalk, S., Leen, A. M. et al.**
Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. *Blood* 2007; vol 110: pp 2838-2845.
41. **Huang, J., Khong, H. T., Dudley, M. E. et al.**
Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. *J. Immunother.* 2005; vol 28: pp 258-267.
42. **Robbins, P. F., Dudley, M. E., Wunderlich, J. et al.**
Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. *J. Immunol.* 2004; vol 173: pp 7125-7130.
43. **Warren, E. H., Fujii, N., Akatsuka, Y. et al.**
Therapy of relapsed leukemia after allogeneic hematopoietic cell transplant with T cells specific for minor histocompatibility antigens. *Blood* 2010; vol
44. **Yee, C., Thompson, J. A., Byrd, D. et al.**
Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. *Proc. Natl. Acad. Sci. U. S. A* 2002; vol 99: pp 16168-16173.
45. **Einsele, H., Roosnek, E., Rufer, N. et al.**
Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. *Blood* 2002; vol 99: pp 3916-3922.
46. **Heslop, H. E., Slobod, K. S., Pule, M. A. et al.**
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. *Blood* 2010; vol 115: pp 925-935.
47. **Peggs, K. S., Verfuert, S., Pizzey, A. et al.**
Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. *Lancet* 2003; vol 362: pp 1375-1377.
48. **Walter, E. A., Greenberg, P. D., Gilbert, M. J. et al.**
Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. *N. Engl. J. Med.* 1995; vol 333: pp 1038-1044.

49. **Dudley, M. E., Wunderlich, J., Nishimura, M. I. et al.**
Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. *J. Immunother.* 2001; vol 24: pp 363-373.
50. **Gattinoni, L., Klebanoff, C. A., Palmer, D. C. et al.**
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. *J. Clin. Invest* 2005; vol 115: pp 1616-1626.
51. **Nijmeijer, B. A., Willemze, R., and Falkenburg, J. H.**
An animal model for human cellular immunotherapy: specific eradication of human acute lymphoblastic leukemia by cytotoxic T lymphocytes in NOD/scid mice. *Blood* 2002; vol 100: pp 654-660.
52. **Sauer, M. G., Ericson, M. E., Weigel, B. J. et al.**
A novel system for simultaneous in vivo tracking and biological assessment of leukemia cells and ex vivo generated leukemia-reactive cytotoxic T cells. *Cancer Res.* 2004; vol 64: pp 3914-3921.
53. **Shen, X., Zhou, J., Hathcock, K. S. et al.**
Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. *J. Immunother.* 2007; vol 30: pp 123-129.
54. **Zhou, J., Shen, X., Huang, J. et al.**
Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. *J. Immunol.* 2005; vol 175: pp 7046-7052.
55. **Powell, D. J., Jr., Dudley, M. E., Robbins, P. F. et al.**
Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. *Blood* 2005; vol 105: pp 241-250.
56. **Berger, C., Jensen, M. C., Lansdorf, P. M. et al.**
Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. *J. Clin. Invest* 2008; vol 118: pp 294-305.
57. **Sallusto, F., Geginat, J., and Lanzavecchia, A.**
Central memory and effector memory T cell subsets: function, generation, and maintenance. *Annu. Rev. Immunol.* 2004; vol 22: pp 745-763.
58. **Wherry, E. J., Blattman, J. N., Murali-Krishna, K. et al.**
Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. *J. Virol.* 2003; vol 77: pp 4911-4927.
59. **Klebanoff, C. A., Gattinoni, L., Torabi-Parizi, P. et al.**
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. *Proc. Natl. Acad. Sci. U. S. A.* 2005; vol 102: pp 9571-9576.
60. **Gattinoni, L., Zhong, X. S., Palmer, D. C. et al.**
Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. *Nat. Med.* 2009; vol 15: pp 808-813.
61. **Appay, V., Dunbar, P. R., Callan, M. et al.**
Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. *Nat. Med.* 2002; vol 8: pp 379-385.
62. **Appay, V., van Lier, R. A., Sallusto, F. et al.**
Phenotype and function of human T lymphocyte subsets: Consensus and issues. *Cytometry A* 2008; vol
63. **Hislop, A. D., Gudgeon, N. H., Callan, M. F. et al.**
EBV-specific CD8+ T cell memory: relationships between epitope specificity, cell phenotype, and immediate effector function. *J. Immunol.* 2001; vol 167: pp 2019-2029.
64. **Rossig, C., Bollard, C. M., Nuchtern, J. G. et al.**
Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. *Blood* 2002; vol 99: pp 2009-2016.
65. **Amir, A. L., D'Orsogna, L. J., Roelen, D. L. et al.**
Allo-HLA reactivity of virus-specific memory T cells is common. *Blood* 2010; vol 115: pp 3146-3157.
66. **Pule, M. A., Savoldo, B., Myers, G. D. et al.**
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. *Nat. Med.* 2008; vol 14: pp 1264-1270.
67. **Teague, R. M., Greenberg, P. D., Fowler, C. et al.**
Peripheral CD8+ T cell tolerance to self-proteins is regulated proximally at the T cell receptor. *Immunity.* 2008; vol 28: pp 662-674.
68. **Cooper, L. J., Topp, M. S., Pinzon, C. et al.**
Enhanced transgene expression in quiescent and activated human CD8+ T cells. *Hum. Gene Ther.* 2004; vol 15: pp 648-658.
69. **Plavec, I., Agarwal, M., Ho, K. E. et al.**
High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS. *Gene Ther.* 1997; vol 4: pp 128-139.
70. **Pollok, K. E., van Der Loo, J. C., Cooper, R. J. et al.**
Costimulation of transduced T lymphocytes via T cell receptor-CD3 complex and CD28 leads to increased transcription of integrated retrovirus. *Hum. Gene Ther.* 1999; vol 10: pp 2221-2236.
71. **Cohen, C. J., Zhao, Y., Zheng, Z. et al.**
Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. *Cancer Res.* 2006; vol 66: pp 8878-8886.
72. **Kershaw, M. H., Westwood, J. A., Parker, L. L. et al.**
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. *Clin. Cancer Res.* 2006; vol 12: pp 6106-6115.
73. **Bialer, G., Horowitz-Fried, M., Ya'acobi, S. et al.**
Selected murine residues endow human TCR with enhanced tumor recognition. *J. Immunol.* 2010; vol 184: pp 6232-6241.
74. **Sommermeier, D. and Uckert, W.**
Minimal amino acid exchange in human TCR constant regions fosters improved function of TCR gene-modified T cells. *J. Immunol.* 2010; vol 184: pp 6223-6231.
75. **Cohen, C. J., Li, Y. F., El-Gamil, M. et al.**
Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. *Cancer Res.* 2007; vol 67: pp 3898-3903.
76. **Kuball, J., Dossett, M. L., Wolff, M. et al.**
Facilitating matched pairing and expression of TCR chains introduced into human T cells. *Blood* 2007; vol 109: pp 2331-2338.

77. **Bendle, G. M., Haanen, J. B., and Schumacher, T. N.**
Preclinical development of T cell receptor gene therapy.
Curr. Opin. Immunol. 2009; vol 21: pp 209-214.
78. **van der Veken, L. T., Hagedoorn, R. S., van Loenen, M. M. et al.**
Alphabeta T-cell receptor engineered gammadelta T cells mediate effective antileukemic reactivity.
Cancer Res. 2006; vol 66: pp 3331-3337.
79. **van der Veken, L.T., Coccoris, M., Swart, E. et al.**
Alphabeta T cell receptor transfer to gammadelta T cells generates functional effector cells without mixed TCR dimers in vivo.
J. Immunol. 2009; vol 182: pp 164-170.
80. **van Lent, A. U., Nagasawa, M., van Loenen, M. M. et al.**
Functional human antigen-specific T cells produced in vitro using retroviral T cell receptor transfer into hematopoietic progenitors.
J. Immunol. 2007; vol 179: pp 4959-4968.
81. **Day, E. K., Carmichael, A. J., ten Berge, I. et al.**
Rapid CD8+ T Cell Repertoire Focusing and Selection of High-Affinity Clones into Memory Following Primary Infection with a Persistent Human Virus: Human Cytomegalovirus.
J. Immunol. 2007; vol 179: pp 3203-3213.
82. **Silins, S. L., Cross, S. M., Krauer, K. G. et al.**
A functional link for major TCR expansions in healthy adults caused by persistent Epstein-Barr virus infection.
J. Clin. Invest 1998; vol 102: pp 1551-1558.
83. **Bendle, G. M., Linnemann, C., Hooijkaas, A. I. et al.**
Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy.
Nat. Med. 2010; vol 16: pp 565-70, 1p.
84. **Bollard, C. M., Aguilar, L., Straathof, K. C. et al.**
Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease.
J. Exp. Med. 2004; vol 200: pp 1623-1633.
85. **Cobbold, M., Khan, N., Pourghesari, B. et al.**
Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers.
J. Exp. Med. 2005; vol 202: pp 379-386.
86. **Khanna, R., Bell, S., Sherritt, M. et al.**
Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.
Proc. Natl. Acad. Sci. U. S. A 1999; vol 96: pp 10391-10396.
87. **Riddell, S. R., Watanabe, K. S., Goodrich, J. M. et al.**
Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones.
Science 1992; vol 257: pp 238-241.
88. **Rooney, C. M., Smith, C. A., Ng, C. Y. et al.**
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation.
Lancet 1995; vol 345: pp 9-13.
89. **Savoldo, B., Goss, J. A., Hammer, M. M. et al.**
Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs).
Blood 2006; vol 108: pp 2942-2949.